Remedy Plan Logo: Remedy Plan Therapeutics

  • Science
  • Pipeline
  • Team
  • Media
  • Careers

Categories

  • All
  • Media
  • Archived Posts
  • Lab Notes

Remedy Plan Therapeutics Initiates Dosing in Phase 1 Clinical Trial of RPT1G, a First-In-Class Hyperbolic NAMPT Inhibitor

Parisa Moghaddam-Taaheri on December 1, 2024 in Media

Read More

UPDATE - Remedy Plan Therapeutics Showcases Preclinical Data from First-In-Class NAMPT Inhibitor, RPT1G, Demonstrating Synergy with BCL-2 Family Inhibitors in AML at the 2024 ASH Annual Meeting

Parisa Moghaddam-Taaheri on December 1, 2024 in Media

Read More

Remedy Plan Therapeutics Announces Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

Parisa Moghaddam-Taaheri on November 1, 2024 in Media

Read More

Remedy Plan Therapeutics Showcases Novel NAMPT Inhibitor During Podium Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Parisa Moghaddam-Taaheri on January 1, 2024 in Media

Read More

Remedy Plan Therapeutics to Showcase Novel NAMPT Inhibitor During Oral Presentation at 2023 American Society of Hematology (ASH) Annual Meeting

Parisa Moghaddam-Taaheri on December 1, 2023 in Media

Read More

  • « Older

Remedy Plan Logo: Remedy Plan Therapeutics

Navigation

  • Science
  • Pipeline
  • Team
  • Media
  • Careers

Contact

To get in touch, email us at
[email protected].

Stay Informed

We'll send you updates every few months, and will never share your information with anyone else.

Social

  • LinkedIn
  • AngelList
  • CrunchBase